Results
EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma
7 Nov 2023
Post
The European Organisation for Research and Treatment of Cancer (EORTC) is pleased to announce a collaboration with Immunocore, which marks the beginning of the ground-breaking clinical trial ATOM investigating the adjuvant treatment of uveal melanoma with tebentafusp. This partnership marks a crucial step forward in our mission to enhance the prognosis and treatment options [...]
EORTC Melanoma Group Spring Meeting
25 Oct 2023
Event
The EORTC Melanoma Group Spring meeting will be held in Turin, Italy on 21-22 March 2024. It is only open to individual or site staff members of the group. Registrations for the meeting are open and the link was sent by email. In case you are an individual or site staff member of the EORTC [...]
EORTC Melanoma Group Autumn Meeting
17 May 2023
Event
The EORTC Melanoma Group Autumn meeting will be held in Manchester, UK on 5-6 October 2023. It is only open to individual or site staff members of the group. Registrations for the meeting are open and the link was sent by email. In case you are an individual or site staff member of the EORTC [...]
EORTC Melanoma Group Spring Meeting
4 Jan 2023
Event
The EORTC Melanoma Group Spring Meeting will be held as a face-to-face event in Berlin, Germany on 23-24 March and is only open to individual or site staff members of the group. Registrations for the meeting are open and the link was sent by email. In case you are an individual or site staff member [...]
New results, updates, and forthcoming EORTC trials in melanoma, soft tissue sarcoma, head and neck, testicular and lung cancer presented at ESMO 2022
9 Sep 2022
Post
Important new results from EORTC trials will be presented at this year's ESMO conference starting tomorrow (October 9) in Paris. Once again, immunotherapy - the use of drugs that stimulate the immune system so that it can find and attack cancer cells – plays a leading role, as do studies into patients’ quality of [...]
EORTC Completes Patient Recruitment to Study of Treatment for unresectable or metastatic melanoma
5 Aug 2022
Post
Brussels, August 05, 2022 – The European Organisation for Research and Treatment of Cancer (EORTC) has finished patient recruitment for the EORTC-1612-MG trial in patients with unresected or metastatic melanoma. The randomised trial will study the effect of combined targeted therapy (encorafenib and binimetinib) followed by combined immunotherapy (ipilimumab and nivolumab) as compared to [...]
